Patents by Inventor Thomas Egebjerg

Thomas Egebjerg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
    Publication number: 20260035450
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Application
    Filed: September 11, 2025
    Publication date: February 5, 2026
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS
    Publication number: 20250333496
    Abstract: The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).
    Type: Application
    Filed: July 10, 2025
    Publication date: October 30, 2025
    Inventors: Thomas Egebjerg, Jais Rose Bjelke, Che Yang, Steffen Reedtz-Runge, Katharina Luise Maria Kopp, Emma Balantic-Nielsen, Philip Jonas Sassene
  • Anti IL-6 domain antibodies with fatty acid substituents
    Patent number: 12404325
    Abstract: The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).
    Type: Grant
    Filed: September 11, 2024
    Date of Patent: September 2, 2025
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Egebjerg, Jais Rose Bjelke, Che Yang, Steffen Reedtz-Runge, Katharina Luise Maria Kopp, Emma Balantic-Nielsen, Philip Jonas Sassene
  • ANTI IL-6 DOMAIN ANTIBODIES
    Publication number: 20250101094
    Abstract: The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).
    Type: Application
    Filed: September 11, 2024
    Publication date: March 27, 2025
    Inventors: Thomas Egebjerg, Jais Rose Bjelke, Che Yang, Steffen Reedtz-Runge, Katharina Luise Maria Kopp, Emma Balantic-Nielsen, Philip Jonas Sassene
  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240425837
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: August 21, 2024
    Publication date: December 26, 2024
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jones Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • Highly potent ISVD compounds capable of substituting for FVIII(A)
    Patent number: 12098400
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: September 24, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
    Publication number: 20240043516
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Application
    Filed: September 5, 2023
    Publication date: February 8, 2024
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
    Publication number: 20230348582
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 2, 2023
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
    Patent number: 11780910
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: October 10, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • Targeting tissue factor to activated platelets
    Publication number: 20190062429
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: September 13, 2018
    Publication date: February 28, 2019
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Targeting tissue factor to activated platelets
    Patent number: 10106606
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 23, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Targeting Tissue Factor To Activated Platelets
    Publication number: 20160272710
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: April 4, 2016
    Publication date: September 22, 2016
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg
  • Activatable Constructs
    Publication number: 20130052192
    Abstract: The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells.
    Type: Application
    Filed: February 18, 2011
    Publication date: February 28, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Jais Rose Bjelke, Susanne Nedergaard Grell, Thomas Egebjerg
  • TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS
    Publication number: 20120178908
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: August 26, 2010
    Publication date: July 12, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjeike, Thomas Egebjerg